DNA
Ginkgo Bioworks Holdings, Inc.NYSEHealthcare$6.90+1.62%ClosedMarket Cap: $427.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.75
P/S
2.51
EV/EBITDA
-3.14
DCF Value
$-37.91
FCF Yield
-45.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.5%
Operating Margin
-185.3%
Net Margin
-183.8%
ROE
-53.7%
ROA
-29.4%
ROIC
-30.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $33.4M | 124.4% | $-70.8M | $-80.8M | $-1.43 | — |
| FY 2025 | $170.2M | 81.5% | $-315.3M | $-312.8M | $-5.64 | — |
| Q3 2025 | $38.8M | 67.0% | $-90.0M | $-80.8M | $-1.45 | — |
| Q2 2025 | $49.6M | 70.1% | $-65.5M | $-60.3M | $-1.10 | — |
| Q1 2025 | $48.3M | 75.1% | $-89.0M | $-91.0M | $-1.68 | — |
| Q4 2024 | $43.8M | 78.1% | $-103.6M | $-107.5M | $-2.07 | — |
| FY 2024 | $227.0M | 83.0% | $-559.8M | $-547.0M | $-10.54 | — |
| Q3 2024 | $89.0M | 88.8% | $-55.2M | $-56.4M | $-1.08 | — |
| Q2 2024 | $56.2M | 75.6% | $-222.9M | $-217.2M | $-4.23 | — |
| Q1 2024 | $37.9M | 75.7% | $-178.0M | $-165.9M | $-3.32 | — |
| Q4 2023 | $34.8M | 81.0% | $-178.1M | $-211.7M | $-4.31 | — |
| FY 2023 | $251.5M | 78.5% | $-864.4M | $-892.9M | $-18.40 | — |